Moderna’s latest melanoma data have done nothing to settle the argument that matters most for the stock: whether a personalized cancer therapy can earn its keep once the manufacturing bill comes due. Citi weighed in on Friday by reaffirming its sell rating and an $80 price target, a reminder that a convincing clinical result and a convincing equity story are two different things.
The numbers themselves are strong. In the Phase III INTerpath-001 trial, which enrolled 1,137 patients with fully resected high-risk melanoma, the combination of Intismeran Autogene and Keytruda cut the risk of recurrence or death by 42% versus Keytruda alone. The risk of distant metastasis or death fell by 38%. Because the comparator was an active treatment rather than a placebo, the benefit is measured against something already working. Median follow-up stood at 24.6 months, according to the companies.
Recurrence-free survival is where the case rests. At two years, 82.2% of patients on the combination had not relapsed, against 70% on Keytruda alone. Whether that gap holds as observation continues will determine how much of it regulators are willing to credit.
A Curve That Bends Late
The timing of the benefit deserves a closer look. Over the first six months, the hazard ratio for recurrence or death was 0.99 — essentially no separation between the arms. A prespecified sensitivity analysis covering the period afterward reported a hazard ratio of 0.42. That divergence is meaningful for investors, but it does not substitute for the trial’s overall result, and the durability of the later advantage still has to be confirmed by further follow-up. Nor should a single favorable cut of the data become the whole valuation case.
Overall survival remains the missing piece. A benefit on the combined recurrence-or-death endpoint does not establish a survival advantage, and those data are not yet mature. The treatment cannot yet be described as proven to extend life.
Safety looked manageable. Treatment-related adverse events of grade three to five occurred in 14.2% of patients on the combination and 13.4% on Keytruda alone, with no new safety signals reported. Long-term tolerability still needs watching.
Should investors sell immediately? Or is it worth buying Moderna?
Citi Asks the Awkward Question
Friday’s note from Citi framed the debate squarely: does the treatment benefit justify the individualized collection of tumor material and the manufacturing that follows? That is a challenge to the size of the payoff relative to the effort, not a denial that a benefit exists. Reading the skeptical reaction as a verdict on the data themselves misses the point.
The market’s mood has been sour regardless. Shares were down 6.4% on the day, and Reuters reported that the detailed results had leaked ahead of their planned presentation. The news agency tied the sharp declines that followed both to the data and to lofty expectations, while the Washington Post reported that analysts had attributed part of the earlier slide to overly high hopes. Jefferies called the data encouraging, and UBS said the results bolstered confidence in follow-on studies. Neither view amounts to an approval guarantee or a locked-in revenue stream.
Beyond Melanoma, a Manufacturing Question
Moderna and Merck are also running nine Phase II and Phase III studies across several tumor types, including three Phase III trials in non-small cell lung cancer. On the production side, the companies say personalized manufacturing succeeded for more than 99% of assigned patients. That high success rate answers a technical question, not the commercial one: personalized production is regarded as complex and costly, and scalability and affordability remain unresolved. A strong hit rate in the plant does not by itself deliver broad, affordable access.
The bull case requires several things to line up at once — durable recurrence protection, a workable path through regulators, and a therapy that can be made and paid for at scale. Approval is spoken of as a possibility in 2027, with no firm decision date attached, and the upcoming publication in the New England Journal of Medicine should draw fresh scrutiny to the dataset. Clinical efficacy, manufacturability and commercial viability are separate tests. Until they converge, the melanoma result stands as genuine scientific progress — and as an investment case still waiting on its arithmetic.
Ad
Moderna Stock: Buy or Sell?! New Moderna Analysis from October 26 delivers the answer:
The latest Moderna figures speak for themselves: Urgent action needed for Moderna investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from October 26.
Moderna: Buy or sell? Read more here...
